Evidence map›Paper›PMID 33790420›Full record

Trial reportProstate cancer and prostatic diseases2021

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study.

A I Peltomaa, P Raittinen, K Talala, K Taari, T L J Tammela, A Auvinen, T J Murtola

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Prostate cancer and prostatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Statins and Cancer Prevention-Association Does Not Mean Causation.Cancer prevention research (Philadelphia, Pa.) · 2023
    Article
  15. Article
  16. Targeting lipid metabolism in metastatic prostate cancer.Therapeutic advances in medical oncology · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

A I PeltomaaUniversity of Tampere, School of Medicine, Tampere, Finland. antti.peltomaa@tuni.fi.ORCID http://orcid.org/0000-0002-5731-0515
P RaittinenDepartment of Mathematics and Systems Analysis, Aalto University, School of Science, Espoo, Finland.
K TalalaFinnish Cancer Registry, Helsinki, Finland.
K TaariDepartment of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
T L J TammelaDepartment of Urology, Tampere University Hospital, Tampere, Finland.
A Auvinen *University of Tampere, School of Health Sciences, Tampere, Finland.
T J Murtola *Department of Urology, Tampere University Hospital, Tampere, Finland.
Tampere University Hospital · FIAalto University · FIFinnish Cancer Registry · FITampere University · FITampere University of Applied Sciences · FIUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeStatins' cholesterol-lowering efficacy is well-known. Recent epidemiological studies have found that inhibition of cholesterol synthesis may have beneficial effects on prostate cancer (PCa) patients, especially patients treated with androgen deprivation therapy (ADT). We evaluated statins' effect on prostate cancer prognosis among patients treated with ADT. MATERIALS AND

methodsOur study population consisted of 8253 PCa patients detected among the study population of the Finnish randomized study of screening for prostate cancer. These were limited to 4428 men who initiated ADT during the follow-up. Cox proportional regression model adjusted for tumor clinical characteristics and comorbidities was used to estimate hazard ratios for risk of PSA relapse after ADT initiation and prostate cancer death.

resultsDuring the median follow-up of 6.3 years after the ADT initiation, there were 834 PCa deaths and 1565 PSA relapses in a study cohort. Statin use after ADT was associated with a decreased risk of PSA relapse (HR 0.73, 95% CI 0.65-0.82) and prostate cancer death (HR 0.82; 95% CI 0.69-0.96). In contrast, statin use defined with a one-year lag (HR 0.89, 95% CI 0.76-1.04), statin use before ADT initiation (HR 1.12, 95% CI 0.96-1.31), and use in the first year on ADT (HR 1.02, 95% CI 0.85-1.24) were not associated with prostate cancer death, without dose dependency.

conclusionStatin use after initiation of ADT, but not before, was associated with improved prostate cancer prognosis.

Indexed as

AgedAndrogen AntagonistsCase-Control StudiesDisease ProgressionDrug Therapy, CombinationFinlandFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPrognosisProstatic NeoplasmsSurvival RateAndrogen AntagonistsHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID33790420
PMCPMC8384625
OpenAlexW3142662922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.